Sarepta Therapeutics said Monday that it will receive $1.15 billion in cash and an equity investment from Roche in exchange for international rights to its experimental gene therapy for Duchenne muscular dystrophy.
For Roche, tying up with Sarepta deepens the Swiss pharma giant’s commitment to the field of gene therapy following its $4.8 billion acquisition of Spark Therapeutics, expected to close soon. For Sarepta, partnering with Roche gives the Cambridge, Mass.-based biotech the ability to market its gene therapy outside the U.S., where it lacks a presence today.
About the Author Reprints
